康泰生物成立于 1992 年，现已发展成为中国乙肝疫苗的主导制造商，被列入 "中国医药创新百强企业 "第一梯队。在过去的 30 年里，康泰已售出超过 10 亿剂乙肝疫苗，保护了超过 3 亿人的免疫，为国家节省了超过 1600 亿元的公共卫生支出。 截至 2020 年，康泰生物的已上市产品和研发数量位居中国疫苗行业第一，包括 30 多个自主研发产品。2021年5月，康泰生物自主研发的新冠灭活病毒疫苗在中国获批紧急使用，至7月，已经为抗疫事业贡献超400万剂疫苗。 Founded in 1992, BioKangtai has developed into the Dominant Manufacturer of Hepatitis B Vaccine in China, listed in the first tier of “Top 100 Chinese Pharmaceutical Innovation Enterprises”. Over the last 3 decades, BioKangtai has sold more than 1 billion doses of Hepatitis B vaccine, protected more than 300 million people by immunization and saved public health expenditure for the country by more than 160 billion RMB. After decades of investment, the number of launched products and pipelines in BioKangtai ranks first in China vaccine industry, including our Covid-19 inactivated vaccine that has vaccinated for more than 4 million times in China.